Mark W. Kunkel

1.9k citations

36 papers · 1.3k indexed · h-index 21

Impact in

Molecular Biology top 10%
- Receptor Mechanisms and Signaling
- Redox biology and oxidative stress
- Protein Kinase Regulation and GTPase Signaling
- Cancer therapeutics and mechanisms
Toxicology top 10%

Papers in

Toxicology 2
- Bioactive Compounds and Antitumor Agents 2
Molecular Biology 24
- Redox biology and oxidative stress 4
- Cancer therapeutics and mechanisms 3
- Receptor Mechanisms and Signaling 3
- Protein Kinase Regulation and GTPase Signaling 2

Co-authors: Jacqueline Friedman John A. Johnson Garth Powis R B Clark T J Goka James L. Thomas Robert Lopez‐Ben Richard B. Clark
Journals: Molecular Cancer Therapeutics (4 papers)Journal of Medicinal Chemistry (4 papers)Cancer Research (4 papers)The FASEB Journal (2 papers)JNCI Journal of the National Cancer Institute (1 paper)
Partner nations: United States Italy Canada

In The Last Decade

Mark W. Kunkel

33 papers receiving 1.2k citations

Peers

Countries citing papers authored by Mark W. Kunkel

Since Specialization

Citations

This map shows the geographic impact of Mark W. Kunkel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark W. Kunkel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark W. Kunkel more than expected).

Fields of papers citing papers by Mark W. Kunkel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark W. Kunkel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark W. Kunkel. The network helps show where Mark W. Kunkel may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark W. Kunkel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark W. Kunkel Line = papers co-authored together Mark W. Kunkel links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	HTS384 NCI60: The Next Phase of the NCI60 Screen Cancer Research ·Mark W. Kunkel, Nathan P. Coussens, Joel Morris, Ronald C. Taylor, Thomas S. Dexheimer, Eric M. Jones, James H. Doroshow, Beverly A. Teicher	2024	11
2	Abstract 3090: Development and performance of the National Cancer Institute’s HTS384 NCI60 screen: A modernized platform to support drug discovery and development by the worldwide cancer research community Cancer Research ·Nathan P. Coussens, Thomas S. Dexheimer, Eric M. Jones, Thomas Silvers, 長谷川敏彦, Ronald C. Taylor, Mark W. Kunkel, James H. Doroshow, Beverly A. Teicher	2024	1
3	F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd Molecular Cancer Therapeutics ·Joel Morris, Donn G. Wishka, Omar D. Lopez, SoyeonPark, Hilarius Donatus Hun, Renny Dwijayanti, Suzanne Borgel, Victor Démiaux, John Carter, Howard Stotler, Mark W. Kunkel, Jerry M. Collins, Melinda G. Hollingshead, Beverly A. Teicher	2021	7
4	Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression JNCI Journal of the National Cancer Institute ·Eric C. Polley, Mark W. Kunkel, David M. Evans, Thomas Silvers, René Delosh, Julie Laudeman, Benjamin Ackermann, Russell Reinhart, Michael Selby, John Connelly, Erik Harris, Nicole Fer, Dmitriy Sonkin, Gurmeet Kaur, Anne Monks, Shakun Malik, Joel Morris, Beverly A. Teicher	2016	106
5	Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression Molecular Cancer Therapeutics ·Beverly A. Teicher, Eric C. Polley, Mark W. Kunkel, David M. Evans, Thomas Silvers, René Delosh, Julie Laudeman, Benjamin Ackermann, Russell Reinhart, Michael Selby, John Connelly, Erik Harris, Anne Monks, Joel Morris	2015	55
6	The dichotomy between disease phenotype databases and the implications for understanding complex diseases involving the major histocompatibility complex International Journal of Immunogenetics ·Peter Clark, Mark W. Kunkel, Dimitri Monos	2015	16
7	Abstract 5475: Interrogation of NCI-60 patterns of growth inhibition in conjunction with investigational oncology agents kinase profiling for the elucidation of mechanistic targets Cancer Research ·Joel Morris, Mark W. Kunkel, Eric C. Polley, Susan L. Holbeck, Anne Monks, David M. Evans, Annamaria Rapisarda, Jerry M. Collins, Beverly A. Teicher	2014	0
8	Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages - strategies for data mining in support of therapeutic studies BMC Genomics ·Melinda G. Hollingshead, Luke H. Stockwin, Sergio Y. Alcoser, Dianne L. Newton, Benjamin C. Orsburn, Carrie Bonomi, Suzanne Borgel, Sunil Junapudi, Paul Inwood, Elizabeth Hager, Susan L. Holbeck, Gurmeet Kaur, Deisy Dayana Timana Estrada, Mark W. Kunkel, Greg Pak, Michael E. Mullendore, Howard Stotler, Jerry M. Collins	2014	26
9	SNP-specific extraction of haplotype-resolved targeted genomic regions Nucleic Acids Research ·Johannes Dapprich, Deborah Ferriola, Eleni Magira, Mark W. Kunkel, Dimitri Monos	2008	24
10	Antitumor Activity of Bis-indole Derivatives Journal of Medicinal Chemistry ·Aldo Andreani, Silvia Burnelli, Massimiliano Granaiola, Alberto Leoni, Alessandra Locatelli, Rita Morigi, Mirella Rambaldi, Lucilla Varoli, Laura Landi, Cecilia Prata, Michael V. Berridge, Carole Grasso, Heinz‐Herbert Fiebig, Gerhard Kelter, Angelika M. Burger, Mark W. Kunkel	2008	100
11	Global Mapping of Transposon Location PLoS Genetics ·Abram Gabriel, Johannes Dapprich, Mark W. Kunkel, David Gresham, Stephen C. Pratt, Maitreya J. Dunham	2006	42
12	Radiographic Values of the Adult Foot in a Standardized Population The Journal of Foot & Ankle Surgery ·James L. Thomas, Mark W. Kunkel, Robert Lopez‐Ben, William J. Embro	2006	78
13	Synthesis and Antitumor Activity of Guanylhydrazones from 6-(2,4-Dichloro-5-nitrophenyl)imidazo[2,1-b]thiazoles and 6-Pyridylimidazo[2,1-b]thiazoles Journal of Medicinal Chemistry ·Aldo Andreani, Silvia Burnelli, Massimiliano Granaiola, Alberto Leoni, Alessandra Locatelli, Rita Morigi, Mirella Rambaldi, Lucilla Varoli, Giovanna Farruggia, Claudio Stefanelli, Lanfranco Masotti, Mark W. Kunkel	2006	26
14	Laminin-5-mediated gene expression in human prostate carcinoma cells Molecular Carcinogenesis ·Robert Calaluce, Mark W. Kunkel, George S. Watts, Monika Schmelz, Junshan Hao, muneeba shabbir, Mary Gleason-Guzman, R. Benjamin Isett, Mark Fitchmun, G. Tim Bowden, Anne E. Cress, Bernard W. Futscher, Raymond B. Nagle	2001	21
15	cDNA Microarray Analysis of Multidrug Resistance: Doxorubicin Selection Produces Multiple Defects in Apoptosis Signaling Pathways Journal of Pharmacology and Experimental Therapeutics ·George S. Watts, Bernard W. Futscher, R. Benjamin Isett, Mary Gleason-Guzman, Mark W. Kunkel, Sydney E. Salmon	2001	63
16	3β-Hydroxy-6-aza-cholestane and related analogues as phosphatidylinositol specific phospholipase C (PI-PLC) inhibitors with antitumor activity Bioorganic & Medicinal Chemistry ·Anil Kumar Mysore Ramakrishna, Hairuo Peng, Leon H. Zalkow, S.-W. Park, Cheng Zhu, Garth Powis, Mark W. Kunkel	2000	17
17	Mechanisms of Inhibition of the Thioredoxin Growth Factor System by Antitumor 2-Imidazolyl Disulfides Biochemical Pharmacology ·D. Lynn Kirkpatrick, Prohor Aleksandrovich Polyakov, YELKA CECILIA DARISIC, Noëlle Potier, Lynda J. Donald, Mark W. Kunkel, Margareta Berggren, M. Martín Angulo, Garth Powis	1998	118
18	3-Deoxy-d-myo-inositol 1-Phosphate, 1-Phosphonate, and Ether Lipid Analogues as Inhibitors of Phosphatidylinositol-3-kinase Signaling and Cancer Cell Growth Journal of Medicinal Chemistry ·Lixin Qiao, Fajun Nan, Mark W. Kunkel, Alfred Gallegos, Garth Powis, Alan P. Kozikowski	1998	43
19	Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice Investigational New Drugs ·Mark W. Kunkel, Kenneth E. Hook, Васильченко Юрій Денисович, Sally Przybranowski, Billy Roberts, William L. Elliott, Wilbur R. Leopold	1995	55
20	Cell‐free heterologous desensitization of adenylyl cyclase in S49 lymphoma cell membranes mediated by cAMP‐dependent protein kinase The FASEB Journal ·Mark W. Kunkel, Jacqueline Friedman, Shirish Shenolikar, Richard B. Clark	1989	29

About Mark W. Kunkel

Mark W. Kunkel is a scholar working on Toxicology, Molecular Biology, Cancer Research, Biochemistry and Oncology, having authored 36 papers that have together received 1.3k indexed citations. Recurring topics across this work include Redox biology and oxidative stress (4 papers), Cancer therapeutics and mechanisms (3 papers), Lung Cancer Treatments and Mutations (3 papers), Receptor Mechanisms and Signaling (3 papers), Bioactive Compounds and Antitumor Agents (2 papers), Synthesis and Characterization of Heterocyclic Compounds (2 papers), Protein Kinase Regulation and GTPase Signaling (2 papers) and HER2/EGFR in Cancer Research (2 papers). The work is most often cited by research in Molecular Biology (748 citations), Toxicology (33 citations), Oncology (252 citations), Organic Chemistry (247 citations) and Orthopedics and Sports Medicine (72 citations). Mark W. Kunkel has collaborated with scholars based in United States, Italy and Canada. Frequent co-authors include Jacqueline Friedman, John A. Johnson, Garth Powis, R B Clark, T J Goka, James L. Thomas, Robert Lopez‐Ben, Richard B. Clark, Beverly A. Teicher and Massimiliano Granaiola. Their work appears in journals such as Molecular Cancer Therapeutics, Journal of Medicinal Chemistry, Cancer Research, The FASEB Journal and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact